Qiagen Stock Price, News & Analysis

QIAGEN has introduced a new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis on its QIAcuity platform.

This tool complements QIAGEN's existing pre-designed assays and enhances the GeneGlobe Design and Analysis Hub.

GeneGlobe now features improved user experience, including collaborative panel design and faster pathway map rendering via Ingenuity Pathway Analysis.

These upgrades aim to support diverse assay customization needs, accelerating drug discovery and other research applications.

QIAGEN plans to expand the dPCR tool capabilities to include microbial and somatic mutation assays later in 2024.

QIAGEN has launched the QIAstat-Dx Gastrointestinal Panel 2 in the U.S. following FDA clearance for clinical use. The panel identifies up to 16 GI pathogens in about an hour using real-time PCR technology, improving the efficiency and accuracy of GI infection diagnoses. Acute infectious gastroenteritis is a major health concern in the U.S., with 180 million cases annually. The panel's rapid detection reduces the need for lengthy traditional tests and helps healthcare providers quickly isolate contagious patients. Additionally, it supports antimicrobial stewardship by reducing unnecessary antibiotic use. The QIAstat-Dx system is widely used with over 4,000 installations globally, and it features cloud-based connectivity for remote monitoring and epidemiological insights.

QIAGEN and Myriad Genetics have announced a collaboration to develop a kit-based test for Homologous Recombination Deficiency (HRD). This next-generation sequencing (NGS) test leverages QIAGEN’s QIAseq xHYB technology and Myriad’s FDA-approved MyChoice CDx biomarkers.

The test will support research and companion diagnostics development, aiding personalized medicine for ovarian and other solid tumors. The goal is to enhance decentralized testing, reduce therapy decision times, and lower associated costs.

The MyChoice CDx assay can identify 34% more HRD tumors compared to other methods. This initiative builds on a recently announced collaboration agreement and aims to expand the accessibility and clinical adoption of HRD testing globally.

QIAGEN has introduced its QIAseq Multimodal DNA/RNA Lib Kit, designed to streamline the preparation of DNA and RNA libraries from a single sample for next-generation sequencing (NGS). This new kit aids multiomics studies, important for precision medicine and understanding complex diseases like cancer.

It offers a simplified workflow for whole genome and transcriptome sequencing, reducing sample material and time required. The kit supports various sample types, including blood, FFPE samples, and cfDNA, and is compatible with multiple sequencing platforms, such as Illumina and Element Aviti.

The QIAseq Multimodal Kit's flexibility in generating DNA-only or RNA-only libraries, as well as combined DNA/RNA libraries, enhances efficiency and saves resources in NGS labs. The kit adds to QIAGEN's NGS technology portfolio, which is pivotal in biomarker research and disease surveillance.

QIAGEN has received European IVDR certification for its QIAGEN Clinical Insight Interpret, a clinical decision support software for next-generation sequencing (NGS) in oncology and hereditary applications. This certification ensures the platform complies with the EU's regulatory framework, enhancing patient safety, data transparency, and traceability. The software has already processed over 4 million NGS patient test cases globally. The certified version will be available in Europe by late 2024, facilitating faster and more accurate clinical decision-making.

QIAGEN has received FDA clearance for its QIAstat-Dx Respiratory Panel Plus, a syndromic test for diagnosing upper respiratory infections. The panel covers 21 viral and bacterial targets, delivers results in about an hour with minimal hands-on time, and provides access to Ct values and amplification curves. This technology aims to improve patient care, support antimicrobial stewardship, and reduce healthcare system burden. QIAGEN is expanding its testing menu, with a Gastrointestinal Panel under FDA review. The company also launched the QIAstat-Dx Analyzer 2.0, featuring cloud-based connectivity and remote result access, enhancing collaboration in healthcare.

QIAGEN partners with the FBI to develop a novel digital PCR assay for QIAcuity to enhance DNA analysis in forensics, improving accuracy, speed, and reliability in human identification. The collaboration aims to quantify DNA from human samples for forensic use, strengthening QIAGEN's leadership in human identification and forensics.

QIAGEN has launched QCI Secondary Analysis, a cloud-based software solution that enhances bioinformatics workflows for oncology and inherited disease applications. The software, integrated with QCI Interpret, enables high-throughput secondary analysis of clinical next-generation sequencing data, advancing precision medicine and making NGS testing accessible to smaller labs. The solution provides a secure and compliant environment for bioinformatics workflows, supporting all QIAGEN QIAseq panels.

QIAGEN reported its Q1 2024 results, showcasing net sales of $459 million with a 5% decline, but exceeded expectations with $462 million at constant exchange rates. The company's adjusted operating income margin rose to 25.7% from 25.6% in Q1 2023, with adjusted diluted EPS at $0.46, above the outlook of $0.44. Key growth drivers include double-digit CER growth in QuantiFERON and QIAstat-Dx, resulting in a positive outlook for 2024 with reaffirmed guidance of at least $2.0 billion in net sales and adjusted diluted EPS of at least $2.10 CER.